Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations: JACC State-of-the-Art Review

J Am Coll Cardiol. 2020 Dec 15;76(24):2878-2894. doi: 10.1016/j.jacc.2020.10.020.


Fine particulate air pollution <2.5 μm in diameter (PM2.5) is a major environmental threat to global public health. Multiple national and international medical and governmental organizations have recognized PM2.5 as a risk factor for cardiopulmonary diseases. A growing body of evidence indicates that several personal-level approaches that reduce exposures to PM2.5 can lead to improvements in health endpoints. Novel and forward-thinking strategies including randomized clinical trials are important to validate key aspects (e.g., feasibility, efficacy, health benefits, risks, burden, costs) of the various protective interventions, in particular among real-world susceptible and vulnerable populations. This paper summarizes the discussions and conclusions from an expert workshop, Reducing the Cardiopulmonary Impact of Particulate Matter Air Pollution in High Risk Populations, held on May 29 to 30, 2019, and convened by the National Institutes of Health, the U.S. Environmental Protection Agency, and the U.S. Centers for Disease Control and Prevention.

Keywords: cardiopulmonary disease; cardiovascular disease; fine particulate air pollution; portable air cleaner; randomized clinical trials.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Air Pollution / adverse effects*
  • Clinical Trials as Topic
  • Education
  • Heart Diseases / etiology
  • Heart Diseases / prevention & control*
  • Humans
  • Lung Diseases / etiology
  • Lung Diseases / prevention & control*
  • Particulate Matter / adverse effects*


  • Particulate Matter